Compare Lupin Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs NOVARTIS - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN NOVARTIS LUPIN/
NOVARTIS
 
P/E (TTM) x 107.0 515.6 20.8% View Chart
P/BV x 2.4 28.9 8.4% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 LUPIN   NOVARTIS
EQUITY SHARE DATA
    LUPIN
Mar-19
NOVARTIS
Mar-19
LUPIN/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs986980 100.6%   
Low Rs720600 120.0%   
Sales per share (Unadj.) Rs369.5198.7 185.9%  
Earnings per share (Unadj.) Rs13.421.0 63.9%  
Cash flow per share (Unadj.) Rs37.422.3 168.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs303.7307.5 98.8%  
Shares outstanding (eoy) m452.4924.69 1,832.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.34.0 58.1%   
Avg P/E ratio x63.637.7 168.9%  
P/CF ratio (eoy) x22.835.5 64.3%  
Price / Book Value ratio x2.82.6 109.3%  
Dividend payout %047.7 0.0%   
Avg Mkt Cap Rs m386,06419,508 1,979.0%   
No. of employees `00017.70.6 3,043.7%   
Total wages/salary Rs m31,5131,171 2,690.9%   
Avg. sales/employee Rs Th9,453.88,445.4 111.9%   
Avg. wages/employee Rs Th1,782.02,015.7 88.4%   
Avg. net profit/employee Rs Th343.0891.0 38.5%   
INCOME DATA
Net Sales Rs m167,1824,907 3,407.1%  
Other income Rs m3,640783 465.1%   
Total revenues Rs m170,8225,689 3,002.5%   
Gross profit Rs m28,822123 23,470.8%  
Depreciation Rs m10,85032 34,119.8%   
Interest Rs m3,07816 19,360.4%   
Profit before tax Rs m18,534858 2,160.9%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,017340 2,652.0%   
Profit after tax Rs m6,066518 1,171.6%  
Gross profit margin %17.22.5 688.9%  
Effective tax rate %48.739.6 122.7%   
Net profit margin %3.610.6 34.4%  
BALANCE SHEET DATA
Current assets Rs m138,5368,055 1,720.0%   
Current liabilities Rs m61,2991,850 3,313.3%   
Net working cap to sales %46.2126.4 36.5%  
Current ratio x2.34.4 51.9%  
Inventory Days Days8445 186.1%  
Debtors Days Days11234 331.5%  
Net fixed assets Rs m127,516150 85,124.2%   
Share capital Rs m905123 733.4%   
"Free" reserves Rs m136,5177,469 1,827.9%   
Net worth Rs m137,4227,592 1,810.1%   
Long term debt Rs m66,4170-   
Total assets Rs m279,4949,824 2,844.9%  
Interest coverage x7.054.9 12.8%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.5 119.8%   
Return on assets %3.35.4 60.2%  
Return on equity %4.46.8 64.7%  
Return on capital %8.911.5 77.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41458 103,148.6%   
Fx outflow Rs m22,2821,326 1,680.0%   
Net fx Rs m37,132-1,269 -2,926.7%   
CASH FLOW
From Operations Rs m16,660-1,943 -857.5%  
From Investments Rs m-32,8252,742 -1,197.0%  
From Financial Activity Rs m7,441-298 -2,495.4%  
Net Cashflow Rs m-8,724501 -1,740.2%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 31.9 1.6 1,993.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.5 47.0%  
Shareholders   98,259 41,647 235.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Nov 14, 2019 (Close)

TRACK LUPIN

LUPIN - ALEMBIC PHARMA COMPARISON

COMPARE LUPIN WITH

MARKET STATS